ABSTRACT
In 1990 the Advisory Committee on Novel Foods and Processes (ACNFP) received a submission concerning sheep modified to carry a human gene. The gene coded for Factor IX, a protein involved in blood clotting which is required in the treatment of haemophiliacs. At that stage the company involved had no interest in selling the potentially highly valuable animals carrying the human gene. However, they wished to be able to market the large majority of animals in which modification had not been accomplished. 1
